SI2254870T1 - 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 - Google Patents

1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1

Info

Publication number
SI2254870T1
SI2254870T1 SI200931404A SI200931404A SI2254870T1 SI 2254870 T1 SI2254870 T1 SI 2254870T1 SI 200931404 A SI200931404 A SI 200931404A SI 200931404 A SI200931404 A SI 200931404A SI 2254870 T1 SI2254870 T1 SI 2254870T1
Authority
SI
Slovenia
Prior art keywords
cx3cr1
mcp
benzyl
expression
treatment
Prior art date
Application number
SI200931404A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Guido Furlotti
Giorgina Mangano
Nicola Cazzolla
Barbara Garofalo
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of SI2254870T1 publication Critical patent/SI2254870T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200931404A 2008-03-07 2009-03-05 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 SI2254870T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
PCT/EP2009/052590 WO2009109618A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EP09718467.5A EP2254870B1 (en) 2008-03-07 2009-03-05 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1

Publications (1)

Publication Number Publication Date
SI2254870T1 true SI2254870T1 (sl) 2016-05-31

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931404A SI2254870T1 (sl) 2008-03-07 2009-03-05 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
SI200931705T SI2254869T1 (sl) 2008-03-07 2009-03-05 Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931705T SI2254869T1 (sl) 2008-03-07 2009-03-05 Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40

Country Status (25)

Country Link
US (3) US7919518B2 (sl)
EP (3) EP3181551A1 (sl)
JP (2) JP5509099B2 (sl)
KR (2) KR101581828B1 (sl)
CN (2) CN101952256B (sl)
AR (2) AR070810A1 (sl)
AU (2) AU2009221083B2 (sl)
BR (2) BRPI0907976A2 (sl)
CA (2) CA2712703C (sl)
CY (2) CY1117584T1 (sl)
DK (2) DK2254869T3 (sl)
EA (2) EA019711B1 (sl)
ES (2) ES2569330T3 (sl)
GE (2) GEP20135912B (sl)
HR (2) HRP20160462T1 (sl)
HU (1) HUE027098T2 (sl)
IL (3) IL206893A0 (sl)
LT (1) LT2254869T (sl)
MX (2) MX2010009626A (sl)
PL (2) PL2254870T3 (sl)
PT (1) PT2254869T (sl)
SG (1) SG188177A1 (sl)
SI (2) SI2254870T1 (sl)
UA (2) UA103605C2 (sl)
WO (2) WO2009109613A2 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101581828B1 (ko) * 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
KR101581829B1 (ko) 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
DK2462118T3 (da) * 2009-08-03 2014-08-25 Acraf Fremgangsmåde til fremstilling af 1-benzyl-3-hydroxymethyl-1H-indazol og dets derivater og nødvendige magnesiummellemprodukter
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2013163758A1 (en) * 2012-05-01 2013-11-07 Boyd Shelley Romayne Methods for treating and diagnosing blinding eye diseases
EP2850062B1 (en) 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
US9346762B2 (en) * 2012-05-18 2016-05-24 Sanofi Pyrazole derivatives and their use as LPAR5 antagonists
TWI653988B (zh) 2012-11-09 2019-03-21 Howard University 用於牙齒琺瑯質保護之嵌段共聚物
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
US10202350B2 (en) 2015-06-12 2019-02-12 Vettore, LLC MCT4 inhibitors for treating disease
EP3310353A4 (en) * 2015-06-16 2019-02-06 Translatum Medicus, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
MX2019006893A (es) 2016-12-12 2019-10-09 Vettore Llc Inhibidores heterociclicos de mct4.
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
EP3990433A4 (en) * 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US416359A (en) * 1889-12-03 Sash-fastener
US364371A (en) * 1887-06-07 peice
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
US20040097465A1 (en) 2001-03-15 2004-05-20 Akira Asari ll-12 expression controlling agents
CN100349876C (zh) 2001-11-30 2007-11-21 辛塔医药品有限公司 嘧啶化合物
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
JP4979388B2 (ja) * 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006060194A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
KR101581829B1 (ko) * 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도
KR101581828B1 (ko) * 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
MX2010009625A (es) * 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.

Also Published As

Publication number Publication date
HRP20160462T1 (hr) 2016-06-03
EP3181551A1 (en) 2017-06-21
EA018241B1 (ru) 2013-06-28
JP2011513367A (ja) 2011-04-28
EP2254870B1 (en) 2016-02-24
CY1119252T1 (el) 2018-02-14
SG188177A1 (en) 2013-03-28
EP2254869B1 (en) 2017-05-31
MX2010009623A (es) 2010-09-28
EP2254869A2 (en) 2010-12-01
KR20100131432A (ko) 2010-12-15
UA103605C2 (en) 2013-11-11
IL215579A (en) 2015-06-30
EA019711B1 (ru) 2014-05-30
IL207131A (en) 2013-02-28
US8283348B2 (en) 2012-10-09
EA201071040A1 (ru) 2011-02-28
CN101952256B (zh) 2016-03-16
KR20100133957A (ko) 2010-12-22
CN101952256A (zh) 2011-01-19
IL215579A0 (en) 2011-11-30
EP2254870A2 (en) 2010-12-01
UA105170C2 (en) 2014-04-25
CA2712703A1 (en) 2009-09-11
AR070810A1 (es) 2010-05-05
US20100311744A1 (en) 2010-12-09
HRP20171208T1 (hr) 2017-10-06
US20110160205A1 (en) 2011-06-30
AU2009221089B2 (en) 2013-12-05
ES2637009T3 (es) 2017-10-10
CA2712703C (en) 2016-10-11
AR070811A1 (es) 2010-05-05
CN101945855B (zh) 2014-12-17
US8835481B2 (en) 2014-09-16
BRPI0907977A2 (pt) 2015-08-04
WO2009109618A2 (en) 2009-09-11
PT2254869T (pt) 2017-07-18
AU2009221089A1 (en) 2009-09-11
GEP20135912B (en) 2013-08-26
KR101599867B1 (ko) 2016-03-04
WO2009109613A2 (en) 2009-09-11
KR101581828B1 (ko) 2015-12-31
MX2010009626A (es) 2010-12-20
PL2254870T3 (pl) 2016-07-29
CA2712403A1 (en) 2009-09-11
US20110003874A1 (en) 2011-01-06
ES2569330T3 (es) 2016-05-10
AU2009221083B2 (en) 2013-11-28
CY1117584T1 (el) 2017-04-26
PL2254869T3 (pl) 2017-10-31
CN101945855A (zh) 2011-01-12
WO2009109613A3 (en) 2009-12-10
JP2011513365A (ja) 2011-04-28
IL206893A0 (en) 2010-12-30
DK2254869T3 (en) 2017-09-04
DK2254870T3 (en) 2016-05-17
LT2254869T (lt) 2017-08-10
BRPI0907976A2 (pt) 2015-08-04
WO2009109618A3 (en) 2009-12-10
JP5509099B2 (ja) 2014-06-04
AU2009221083A1 (en) 2009-09-11
US7919518B2 (en) 2011-04-05
GEP20135983B (en) 2013-12-10
HUE027098T2 (en) 2016-08-29
JP5509101B2 (ja) 2014-06-04
SI2254869T1 (sl) 2017-10-30
IL207131A0 (en) 2010-12-30
EA201071038A1 (ru) 2011-02-28
CA2712403C (en) 2017-06-06

Similar Documents

Publication Publication Date Title
HRP20191953T8 (hr) DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
PL2254870T3 (pl) Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
HK1253532A1 (zh) 用於治療變應性、炎性和感染性疾病的嘌呤衍生物
IL207278A0 (en) 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, and cx3cr1
IL210803A0 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
HK1168283A1 (zh) 類的試劑在治療抗胰島素和相關疾病的用途
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
TH0901005786A (th) อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ